NCR3 and Miyoshi myopathy: Due to a reduced expression of activating receptors and their ligands (e.g., CD16, NCR3/NKp30, NKG2D, CD244/2B4/p38 and DNAM-1) [136,137,138], and increased expression of the inhibitory receptors such as KIR2DL1, PD1, TIM3 and TIGIT [139,140] by the surrounding TME, NK cell–mediated killing of cPCs was impaired in MM patients.